Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.

US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN ...

Independence Health System’s Westmoreland Hospital announced that its Heart Lung and Vascular Institute specialists ...

With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

also known as non-valvular AFib or NVAF. Washington Regional’s Walker Heart Institute now offers the Watchman FLX Pro Left ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...